Phase I-III results, trial design
50 stories
The cancellation of 181 NCI grants totaling $317 million in early 2025 has stopped cancer disparity clinical trials in their tracks, according to an AACR report. The biotech and pharma pipelines face disruption as critical early-stage research evaporates.
NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.
At AAIC 2026, CaringAI presented research showing 80% concordance between its AI telephone assessment and clinical review, providing early validation for a digital biomarker in cognitive screening.
Cognivia and Mayo Clinic are zeroing in on non-adherence, missed appointments, and trial dropout—three behavioral factors that inflate clinical trial costs and delay drug development. By making patient behavior measurable, the partnership could help biopharma sponsors de-risk studies and improve real-world evidence.
Lexaria Bioscience commenced dosing in its GLP-1 animal study aiming to outperform Novo Nordisk’s SNAC-based oral delivery. With 11 arms and three new patent filings, the biotech targets differentiation in the booming GLP-1 sector.
The biotech’s novel inhibitor could redefine the JAK2-targeted therapy landscape, with preclinical data supporting disease-modifying potential ahead of a planned IND submission this year. Investors watch for Phase 1 timing.
In a preclinical MOU, HanchorBio will evaluate its CD47/SIRPα asset HCB101 alongside InxMed’s ifebemtinib and OMTX705. The partnership signals a strategic pivot toward using HCB101 as a combination backbone, potentially de-risking the single-indication pipeline and differentiating the asset in a tricky class.
AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
The Congo Ebola outbreak driven by the rare Bundibugyo virus has ballooned to 1,830 cases with zero approved vaccines or treatments, forcing an urgent launch of clinical trials. For biotech and pharma, this emergency opens a race to develop broad-spectrum filovirus countermeasures.
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
With no approved therapies for the Bundibugyo Ebola strain and an outbreak surpassing 500 fatalities, two candidate drugs have begun a clinical trial, and a prophylactic agent trial is imminent. The collaborative effort signals a pivot toward rapid, integrated R&D for neglected filoviruses.
Clearmind Medicine submitted a response to an HHS RFI highlighting its clinical-stage candidate CMND-100, an MEAI-based neuroplastogen for Alcohol Use Disorder. The drug engages 5-HT1A pathways without hallucinogenic effects, offering a novel mechanism for addiction treatment.
The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns.
With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
uniQure’s AMT-130 update validates its gene therapy platform, while NTHI’s NEO212 advancement and an acquisition deal spotlight a busy week for biotech pipelines and dealmaking.
Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
The biopharma sector faces a new espionage threat as attackers steal detailed clinical trial data from Novo Nordisk. Competitors could reverse-engineer GLP-1 trial endpoints and patient responder profiles.
The rare Bundibugyo Ebola virus has infected 782 people and killed 181 in Congo, with a record 72 new cases in one day. No approved vaccine or treatment exists for this strain, creating an urgent gap for biotech and pharma to address with rapid countermeasure development.
Novo Nordisk's oral Wegovy achieved 16.6% mean weight loss at 64 weeks in the Phase III OASIS-4 trial, with 87% of participants losing ≥5% and one-third losing ≥20%. The once-daily pill uses a SNAC absorption enhancer, triggering MHRA approval and a new phase in the GLP-1 obesity drug race.
At ASCO 2026, CStone's CS2009 trispecific antibody targeting PD-1, VEGF, and CTLA-4 revealed a differentiated safety profile and preliminary overall survival potential, positioning it as a next-gen backbone candidate that may outperform current PD-1/VEGF combos and revive CTLA-4 targeting.
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Pfizer and Valneva have reported positive Phase 3 results for their Lyme disease vaccine candidate, VLA15, demonstrating an efficacy rate exceeding 70%. This development marks a significant milestone in addressing the growing public health threat of tick-borne illnesses, potentially offering the first preventative vaccine for the disease in over two decades.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Innovent Biologics' IBI302 (efdamrofusp alfa) successfully met its primary endpoint in the Phase 3 STAR registration trial for neovascular age-related macular degeneration. As the first domestically developed extended-interval treatment in China, it represents a significant shift toward reducing the injection burden for millions of patients.
Monash University and global CRO ClinChoice have established a strategic partnership to streamline the transition of academic research into clinical-stage therapies. The collaboration aims to leverage ClinChoice's full-service clinical trial infrastructure to fast-track Monash’s pipeline of innovative drug candidates.
A groundbreaking medical milestone has been achieved with the development of the first lab-grown oesophagus, offering a transformative treatment for children born with rare congenital conditions. This regenerative medicine breakthrough uses tissue engineering to create functional organs, potentially replacing invasive surgeries that currently rely on repositioning other digestive organs.
iBio is advancing its bispecific antibody strategy to address Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a major unmet medical need. The company expects to select a formal development candidate by the third quarter of 2026, signaling a transition from discovery to preclinical development for its lead cardiovascular program.
RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
Acumen Pharmaceuticals is advancing its lead antibody, sabirnetug, through Phase II clinical trials while leveraging a strategic partnership with JCR Pharmaceuticals for enhanced brain delivery. The company has identified 2026 as a critical catalyst year for data readouts that could validate its unique approach to targeting toxic amyloid-beta oligomers.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
New Zealand has initiated a major genomic medicine trial designed to provide locally-based genetic sequencing for patients battling cancer and rare diseases. By repatriating diagnostic capabilities, the program aims to accelerate treatment timelines and improve health equity across the country's diverse populations.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A comprehensive study published in The Lancet concludes that medicinal cannabis is largely ineffective for treating anxiety, depression, and PTSD. These findings challenge the rapidly growing global market for cannabinoid-based mental health treatments and highlight a significant gap between patient perception and clinical evidence.
ClinCapture has launched a foundational AI integration within its Captivate platform designed to automate the transition from clinical protocols to digital trial environments. By embedding AI into the trial's structural architecture, the company aims to eliminate manual configuration errors and significantly accelerate study launch timelines.
Belite Bio (BLTE) has reported positive Phase 3 DRAGON trial results for its lead candidate, Tinlarebant, demonstrating a 36% reduction in lesion growth for Stargardt disease. The oral therapy is now positioned for a Q2 2026 NDA submission as the company prepares for a $200M-$250M commercial launch.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Researchers are investigating whether GLP-1 receptor agonists like semaglutide could mitigate symptoms of ADHD by modulating dopamine pathways in the brain. While primarily used for diabetes and obesity, anecdotal evidence and early-stage studies suggest a potential role for these blockbuster drugs in treating executive dysfunction and impulsivity.
Vertex Pharmaceuticals reported that its Phase 3 trial for povetacicept met its primary endpoint, showing a 52% reduction in proteinuria for patients with IgA nephropathy. The company plans to file for FDA accelerated approval by the end of March 2026, utilizing a priority review voucher to expedite the process.
Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
A prespecified analysis of the large-scale COSMOS trial has found that daily multivitamin-multimineral supplementation significantly slows markers of biological aging in older adults. The study provides robust clinical evidence that standard nutritional interventions can influence cellular longevity and epigenetic health beyond simple deficiency prevention.
Roche shares declined following the announcement that its oral SERD, giredestrant, failed to meet the primary endpoint in a pivotal Phase III trial for advanced breast cancer. The setback marks a significant blow to Roche's efforts to regain dominance in the HR-positive, HER2-negative oncology market.
AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Neurizon has officially commenced patient dosing for NUZ-001 in the HEALEY ALS Platform Trial, a multi-center study led by Massachusetts General Hospital. This milestone marks a critical transition for the biotech as it seeks to validate its mTOR inhibitor as a disease-modifying therapy for Amyotrophic Lateral Sclerosis.
According to our own tracking database, this category has accumulated 61 clinical trials stories since coverage began. This page aggregates the latest clinical trials stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track phase i-iii results, trial design and surface the angles a domain expert would actually read.
Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.
| Signal | What it tells you |
|---|---|
| Verified by N sources | Confidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated. |
| Impact score (1-10) | Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on. |
| Sentiment | Five-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora. |
| Time stamp | Recency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed. |